1%), compared to Restasis as a reference, confirmed the beneficial role of the cationic charge in enhancing the ocular penetration of CsA [61] in Novasorb cationic emulsions. Single-dose PK data

demonstrated that the 0.05% CsA cationic emulsion was more effective than Restasis at delivering CsA to the cornea (Cmax: 1372 versus 748ng/g; AUC: 26477 versus 14210ng/g.h, resp.). Furthermore, multiple-dose PK confirmed that there was no systemic Inhibitors,research,lifescience,medical absorption, with values below the limit of detection (LOD, 0.1ng/mL) for the CsA-cationic emulsion (see Figure 5). The use of 3H-CsA also demonstrated that the systemic distribution following repeated instillations was indeed low and comparable for both the CsA-cationic

emulsion and Restasis and confirmed that the improved local absorption with the CsA-containing cationic emulsion did not translate into increased systemic CsA levels. Figure 5 (a) Changes Inhibitors,research,lifescience,medical in corneal CsA concentration with time after a www.selleckchem.com/products/Bortezomib.html single unilateral topical administration in pigmented rabbits. Inhibitors,research,lifescience,medical The error bars represent standard errors. (b) Cornea absorption (AUC) following a single instillation in pigmented rabbits. In addition, the electroattractive interactions between the positively charged oil droplets of the cationic emulsion and the negatively charged ocular surface cell epithelia might also explain the 50% lower contact angle observed with cationic trichostatin a clinical trials emulsions versus anionic (negatively charged) emulsions, and the higher spreading coefficient Inhibitors,research,lifescience,medical [18]. A low contact angle, better spreading coefficient, and an increased residence time of the cationic emulsions may all contribute to the better drug absorption of lipophilic drugs solubilized in cationic emulsions. The cationic

emulsions designed for the treatment of dry eye disease (Cyclokat) Inhibitors,research,lifescience,medical and vernal keratoconjunctivitis (Vekacia) were not tested in pharmacodynamic models as there are no reliable experimental models for these pathologies. However, pharmacokinetic studies with CsA cationic emulsions in animal models demonstrated AV-951 (see previous paragraph) that the tissue concentrations of CsA were above the therapeutic concentration (50–300ng/g of tissue according to Kaswan [62]) in both the cornea and conjunctiva. Therefore, the safety and efficacy of these CsA-containing cationic emulsions were first demonstrated in phase II and III clinical trials (see the following section). In contrast, the safety and efficacy of Catioprost (preservative-free latanoprost 0.005% cationic emulsion) was initially evaluated in an established cynomolgus monkey model of ocular hypertension [63], and compared to Xalatan. Both latanoprost formulations shared the same efficacy profile, and the intraocular pressure (IOP) reduction lasted 24h.